Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

A Novel Pathway For Heart Attack & Stroke Prevention

August 21, 2014 9:47 am | by University of Helsinki | News | Comments

Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke. The finding revealed a promising new way to customise a potentially preventive drug for atherosclerosis.

TOPICS:

ADHD Treatment Market Value To Reach $9.9B By 2020

August 21, 2014 9:43 am | by GBI Research | News | Comments

The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to business intelligence provider GBI Research. 

TOPICS:

Pfizer Initiates Expanded Access Program For Advanced Breast Cancer Treatment

August 21, 2014 9:40 am | by Associated Press | News | Comments

Pfizer Inc. announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib.                       

TOPICS:
Advertisement

U.S. Doctor Recovers From Ebola

August 21, 2014 9:36 am | by JEFF MARTIN, Associated Press | News | Comments

At least one of the two American aid workers who were infected with the deadly Ebola virus in Africa has recovered and was to be discharged Thursday from an Atlanta hospital, a spokeswoman for the aid group he was working for said.              

TOPICS:

Lilly Psoriasis Drug Does Well In Late-Stage Test

August 21, 2014 9:31 am | by Associated Press | News | Comments

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.                        

TOPICS:

Drug Czar Promotes Treatment

August 20, 2014 4:43 pm | by DAVE KOLPACK, Associated Press | News | Comments

As the nation's drug czar continues to warn people about the potential death and destruction from substance abuse, he's also encouraging them to tell their stories about treatment and recovery. Usually he starts with himself.         

TOPICS:

Experimental Ebola Drug Shows Promising Results In Monkeys

August 20, 2014 4:41 pm | by LAURAN NEERGAARD, AP Medical Writer | News | Comments

An experimental drug saved monkeys from a virus closely related to Ebola even after symptoms began, Texas researchers reported Wednesday. A drug that targets Ebola in the same way is under development, and the study raises questions about how late after infection treatments might work.

TOPICS:

New Vaccine For Leprosy & TB

August 20, 2014 2:26 pm | by UCLA | News | Comments

The currently available century-old vaccine Bacille Calmette-Guerin, or BCG, provides only partial protection against both tuberculosis and leprosy, so a more potent vaccine is needed to combat both diseases. UCLA-led research may have found a stronger weapon against both diseases.

TOPICS:
Advertisement

UN Urges Ebola Screenings At Airports

August 20, 2014 10:06 am | by JOHN HEILPRIN, Associated Press | News | Comments

Ebola-affected countries should immediately begin exit screening all passengers leaving international airports, sea ports and major ground crossings, the U.N. health agency said.                    

TOPICS:

Government Refuses To Reveal Security Details From Healthcare Site

August 20, 2014 10:02 am | by JACK GILLUM, Associated Press | News | Comments

After promising not to withhold government information over "speculative or abstract fears," the Obama administration has concluded it will not publicly disclose federal records that could shed light on the security of the government's health care website because doing so could "potentially" allow hackers to break in.

TOPICS:

Bristol-Myers Squibb & Celgene Collaborate On Immunotherapy & Chemo Combination

August 20, 2014 9:59 am | by Associated Press | News | Comments

Bristol-Myers Squibb Company and Celgene Corporation announced the establishment of a clinical trial collaboration to evaluate a combination regimen of Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene’s chemotherapy ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension), in a Phase I study.

TOPICS:

Ipsen Appoints New President & CEO

August 20, 2014 9:51 am | by Associated Press | News | Comments

Ipsen announced that Cynthia Schwalm has been named President and CEO of Ipsen N.A., responsible for all commercial and medical affairs operations throughout the region.                     

TOPICS:

Microbial Colony Pickers

August 20, 2014 9:33 am | by Nikita Ernst, Associate Editor | Product Releases | Comments

The QPix™ 400 series of microbial colony pickers offers the unique option to simultaneously detect colonies and quantify fluorescent markers in a pre-screening step before picking.

TOPICS:

Both Types Of Diabetes Caused By Same Mechanism

August 20, 2014 9:25 am | by University of Manchester | News | Comments

Work by scientists at the Universities of Manchester and Auckland suggest that both major forms of diabetes, type-1 and type-2, are the result of the same mechanism.                               

FDA Approves Genzyme's Cerdelga Capsules

August 19, 2014 5:21 pm | by Associated Press | News | Comments

Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration has approved Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients.                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading